We are working hard using technology to defeat cancer
The Growing Challenge
Over 2.9 million patients living with cancer in the UK alone, which is estimated to grow to 4 million patients by 2031. UK still falls behind in Cancer Detection and Survival when compared to the other similar developed countries. As part of standard treatment, many cancer types require Immunotherapy and various forms of targeted therapy. Many patients suffer from Non-response, eventual relapse, or immune-mediated toxicities
Our Vision
The ability to classify response and predict those who might develop toxicity or resistance is key. Considering the significant morbidity and mortality associated with cancer, we predict significant health, time, and financial benefits with AI-powered prediction of treatment response and assessment and disease progression.
Current Prediction Methods
Current predictive methods of using PD-1/PD-L1 and CPS score for immunotherapy response are insufficient. The cause of the varied response to immunotherapy between patients is multifactorial. Response rate is low in the current immunotherapy regimen as a result - eg. 40% in melanoma. Toxicity rate is as high as 55%, the side effects could be life-threatening. Despite the extraordinary advances in cancer treatment, some patients are classified as non-responders or eventually relapse. Others develop potentially life-threatening immune-mediated toxicities.